In this video, Eric A. Klein, MD, discusses the take-home messages from the recent JCO Precision Oncology study, “GPS Assay Association With Long-Term Cancer Outcomes: Twenty-Year Risk of Distant Metastasis and Prostate Cancer–Specific Mortality,” for which he served as senior author. Klein is the Chairman of the Glickman Urological & Kidney Institute and a staff member in the Taussig Cancer Institute at Cleveland Clinic.
Adding SBRT to frontline abiraterone shows benefit in oligometastatic CRPC
September 25th 2023The addition of SBRT to upfront abiraterone acetate and prednisone (AAP) reduced the risk of disease progression or death by 65% compared with AAP alone in patients with oligometastatic castration-resistant prostate cancer.
2 Clarke Drive
Cranbury, NJ 08512